AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 31 min read$RXST

Wilterding Mark sold $54K of RXST

Wilterding Mark (Chief Financial Officer) sold 7,765 shares of RxSight, Inc. (RXST) at $6.96 on 2026-09-02.

Original reporting
SEC EDGAR · Wilterding Mark
Published Sep 3, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 1:58 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RXST
Bearish
medium confidence
Mentioned
$RXST
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXSTBearishLow
01

Why it matters

The CFO's sale reduces insider ownership and may be interpreted as a lack of confidence, though the amount is modest.

02

Market read

Primary relevance is limited to RxSight shareholders; broader market impact is minimal.

03

What to watch

Potential upcoming earnings or product milestones that may offset the negative signal.

Relevance 3/10Novelty 4/10Timing: post-market filing

Background

SEC Form 4 filing disclosed an insider transaction by RxSight's CFO.

Company-level read

Ticker impact

$RXSTBearishMedium confidence
Context

CFO Mark Wilterding sold 7,765 shares for $54,044, reducing his stake to 25,049 shares.

Expected impact

Potential short-term dip of 1‑2% as market digests the sale.

Evidence & confidence

Sale size is modest but involves a senior officer; market typically reacts negatively to CFO disposals.

Market effects

Sector

Minimal impact on the ophthalmic device sector; similar insider sales have not moved the sector.

Regional

No regional effect; company is US‑listed and trade volume is limited.

Global

Negligible on a global scale.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Company
    RxSight, Inc.

    US‑listed ophthalmic device maker (NASDAQ: RXST).

  • Executive
    Mark Wilterding

    Chief Financial Officer of RxSight.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RXST insider trading history →

Related articles

AUG 17
$ALCMed

Adjustable precision vision post-cataract surgery

Alcon and RxSight announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses. RxSight’s Light Adjustable Lens is described as FDA-approved and adjustable after surgery via non-invasive light treatments. Alcon will lead global commercialization, RxSight will handle development and manufacturing and receive royalties on net sales.

nzoptics.co.nz3 min
AUG 14
$RXSTMedAI 8/10

RxSight (RXST) Q2 2026 Earnings Call Transcript

RxSight (RXST) held its Q2 2026 earnings call. The company said it withdrew full-year 2026 guidance and will resume formal guidance in early 2027. Q2 total revenue was $33.7M, including $6.5M from an Alcon collaboration. Product sales were $27.2M, down 19% YoY, with a Q2 net loss of $12.1M.

yahoo.com6 min
AUG 5
$RXSTMedAI 8/10

RxSight, Inc. (RXST): Results of Operations and Financial Condition

RxSight, Inc. (RXST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK Aliso Viejo, Calif. – August 5, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financia

SEC EDGAR 8-K6 min
AUG 1
$RXSTMed

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RxSight, Inc. (NASDAQ: RXST) announced a leadership transition effective July 20, 2026. Aziz Mottiwala will become President and CEO, succeeding Ron Kurtz, M.D., who will remain Chief Medical Officer. Kurtz will also resign from the board, with Mottiwala appointed in his place. The company cited commercial and clinical continuity around its light adjustable lens technology.

hrtoday.in3 min
JUL 20
$RXSTMed

RxSight Lands Tarsus Commercial Leader as CEO

RxSight (Nasdaq: RXST) appointed Aziz Mottiwala as CEO on July 15, replacing Dr. Ron Kurtz, who becomes chief medical officer. Mottiwala previously served as Tarsus Pharmaceuticals’ chief commercial officer. RXST shares rose 7.2% to $5.63 after the news. The article cites RXST’s forecast cuts and a Bank of America price target cut to $6.50, plus an Alcon partnership with $60 million upfront and up to $140 million in milestones.

ocbj.com6 min
JUL 11
$RXSTMedAI 8/10

RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook

RxSight (NASDAQ:RXST) reported Q2 sales of 11 Light Delivery Devices (LDDs) and one LDD rental, lowering sales 20% and leaving an installed base of 1,166 units. Cash, cash equivalents and short-term investments were about $209M. It revised 2026 revenue to $140M-$160M, including $110M-$120M RxSight sales and $30M-$40M Alcon collaboration revenue, and raised gross margin outlook to 73%-75%.

yahoo.com4 min